This stock is no longer traded. It was delisted on July 2, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative immunotherapies engineered to target infectious diseases and cancer. Headquartered in New York City, the company focuses on leveraging its proprietary arenavirus platform technology to create novel vaccine candidates. This platform is designed to induce potent and targeted immune responses by simulating a natural viral infection without causing disease. Hookipa Pharma primarily targets oncology and infectious disease sectors, aiming to address unmet medical needs through robust and durable immune stimulation. The company's approach enables the development of potential treatments that can be more effective and have fewer side effects compared to traditional vaccines and therapies. In the financial market, Hookipa Pharma Inc. serves as an intriguing entity for stakeholders interested in cutting-edge biopharmaceutical research and development, holding considerable potential impact on public health and therapeutic innovation.
Website350 Fifth Avenue
New York, NY, 10118
United States
Summary of May 22's posts. Generated by AI.
Summary of Jun 4's posts. Generated by AI.
Summary of Jan 10's posts. Generated by AI.
Investors talking about HOOK also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.